NCT06498037 2024-07-12
FERRARI
Erasmus Medical Center
Phase 4 Recruiting
Clinical Trials
10 trialsNCT00683995 2020-08-28
A Phase III Clinical Study of KW-2246
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT00684632 2020-08-28
A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT01946555 2016-04-14
RER
Mario Negri Institute for Pharmacological Research
Completed
NCT01809106 2015-12-24
CERP
Mario Negri Institute for Pharmacological Research
Phase 4 Completed
NCT00916890 2014-01-09
Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic Pain
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase 4 Suspended
NCT00842829 2012-10-01
Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 4 Terminated
NCT00459277 2012-01-25
Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Archimedes Development Ltd
Phase 3 Completed
NCT00236327 2011-05-17
Evaluation of the Efficacy and Safety of Fentanyl Delivered by Adhesive Skin Patch in Out-Patients With Chronic Cancer Pain
Janssen Cilag S.A.S.
Phase 4 Terminated
NCT00216658 2011-01-24
Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -
Janssen Pharmaceutical K.K.
Phase 2 Completed